HomePeptides › Cagrilintide

Cagrilintide

AM833

Tier 2 · Clinical Trials
Class
Long-acting amylin analog
Molecular target
Amylin and calcitonin receptors
Sequence / structure
Acylated amylin analog
Evidence tier
Tier 2 — Clinical Trials
Category
Metabolic & Incretin
Emergency card
Signs something is wrong

Severe, persistent pain in the upper abdomen — often boring through to the back — with nausea and vomiting that will not stop. That is the pancreatitis pattern.

What to do now

Stop and seek medical assessment. Persistent vomiting also dehydrates and strains the kidneys — sip fluids.

When it is an emergency

Unrelenting abdominal pain, repeated vomiting, or signs of dehydration → urgent care or ER. And tell any anaesthetist before surgery: these drugs slow stomach emptying and raise the risk of aspiration under anaesthesia.

Any injection — every time

Allergic reaction: hives, swelling of the lips, tongue or throat, wheezing or dizziness can escalate to anaphylaxis within minutes — call 911 immediately. Site infection: spreading redness, heat, swelling, pus or fever is not wait-and-see; an abscess or cellulitis can need drainage or IV antibiotics. Unverified product: grey-market vials are frequently mislabelled or contaminated, so a reaction may be to endotoxin or the wrong contents, not the named compound.

This is not permission or instruction to use this compound. It is harm-reduction information for someone who has already decided to, so that a bad reaction is recognised and treated. When in doubt, get help — embarrassment is survivable.

Biology & mechanism

Amylin is co-secreted with insulin by beta cells and signals satiety through the area postrema. Cagrilintide is a long-acting analog engineered for weekly administration, acting at amylin and calcitonin receptor complexes. Its interest lies in a satiety mechanism largely orthogonal to GLP-1, which is why it is being developed in combination with semaglutide (CagriSema).

What the research actually shows

Phase 2 established weight effects as monotherapy and in combination. Phase 3 combination programmes are ongoing and have reported mixed results against expectations. Not established.

Regulatory status

Not approved. Investigational.

Safety signals

Under investigation. Gastrointestinal effects reported in trials. Human safety not established.

Clinical trial dosing — what the studies actually used

Investigational. Phase 2 titrated to 2.4 mg once weekly SC, alone and combined with semaglutide (CagriSema). Not an established dose.

Reported from clinical trials or FDA labelling as a matter of record. It is not a recommendation, and for unapproved compounds no dose has been shown safe or effective in humans.

We report study doses, not protocols

Above is what was administered in trials or on FDA labels, reported as fact. We do not convert it into a personal protocol, calculate a dose for your body weight, or tell you what to inject or how to reconstitute it — that decision belongs with a licensed physician. See our editorial policy.

References & further reading

Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.

Important notice Forge Bioenergy publishes scientific reference information only. Nothing on this site is medical advice, a therapeutic claim, or a recommendation to use any substance in humans. Many peptides described here are not approved by the FDA for any use, and several are approved only for narrow indications under prescription. We do not publish dosing, administration, or usage protocols. Consult a licensed physician before making any medical decision.